Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Key Takeaways of J.P. Morgan Healthcare Conference 2025
Key Takeaways of J.P. Morgan Healthcare Conference 2025
Shots:  The 43rd Annual J.P. Morgan Conference took place from 13th to 16th January in San Francisco, USA. J.P. Morgan Healthcare Conference serves as a pioneering hub that features presentations and dialogues on the advances of the healthcare industry by bringing healthcare professionals, researchers, manufacturers, and other healthcare stakeholders to one platform.   Innovation remained the…
January 28, 2025
EMA Marketing Authorization of New Drugs in December 2024
EMA Marketing Authorization of New Drugs in December 2024
Shots:    The EMA’s CHMP has granted positive opinions to 5 Biologics and 4 New Chemical Entities in December 2024, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Galderma’s Nemluvio to treat Prurigo Nodularis and Atopic Dermatitis    PharmaShots has compiled a list of 9 drugs that have been granted positive…
January 23, 2025
Disease of the Month – Epilepsy
Disease of the Month – Epilepsy
Shots:  Epilepsy is a chronic, non-communicable brain condition that affects neurons and causes recurring seizures Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry players advancing treatments for epilepsy For a detailed analysis and tailored…
January 21, 2025
Know Your Investor RA Capital Management (January’25 Edition)
Know Your Investor: RA Capital Management (January’25 Edition)
Shots:    The January Edition features RA Capital Management, a global multi-stage investment firm dedicated to healthcare and life sciences  In 2024, RA Capital added 74 companies to its portfolio, investing approximately $8.5B across seven funding rounds, including private and common funding  Welcome to the 2025 series of Know Your Investor, a meticulously crafted report highlighting…
January 16, 2025
J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)
J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)
Shots:   In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…
January 15, 2025
The US FDA New Drug Approvals in December 2024
The US FDA New Drug Approvals in December 2024
Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of December 2024      The US FDA has approved a total of 10 new drugs including 4 new molecular entities and 6 biologics leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was BMS’ Opdivo Qvantig…
January 14, 2025
PharmaShots’ Key Highlights of Fourth Quarter 2024
PharmaShots’ Key Highlights of Fourth Quarter 2024
Shots:  The Fourth quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Roche's acquisition of Poseida Therapeutics for ~$1.5B  This quarter also showcased multiple clinical trial results including Pfizer's P-III Study Data of Talzenna + Xtandi to treat mCRPC …
January 13, 2025
J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)
J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)
Shots:  The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024  Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion   Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…
January 8, 2025
Key Biosimilars Events of December 2024
Key Biosimilars Events of December 2024
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients A major highlight was the US FDA’s approval of Biocon Biologics’ Yesintek…
January 7, 2025
Key Biosimilars Events of December 2024
Key Biosimilars Events of December 2024
Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        A major highlight was the US FDA’s approval of Biocon Biologics’ Yesintek…
January 7, 2025
Load more